SWOG 2308: Randomized Phase III Study of Mosunetuzumab Versus Rituximab for Low–Tumor Burden Follicular Lymphoma
JCO Oncology Advances · 2025-04 · (2)
DOI: 10.1200/oa-25-00037 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Oncology Advances, 2025-04. Verfasst von Nilanjan Ghosh und 8 weiteren Autor:innen. Beteiligte Einrichtung: Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, NC. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 8 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
BACKGROUNDFollicular lymphoma (FL) is the second most common non-Hodgkin's lymphoma and currently considered incurable with standard therapies.1 The majority of patients present with advanced disease, and many of them are asymptomatic at diagnosis.Current guidelines for management include active surveillance or rituximab monotherapy for patients who present with low-tumor burden FL. 2 Data from the National LymphoCare study show that active surveillance and rituximab monotherapy are commonly applied for this disease presentation.3 Active surveillance does not change the natural history of the disease, and a lifetime risk of progression and potential transformation often lead to patient anxiety.4 The availability of potentially curative immunotherapy options with lesser toxicity compared with chemotherapy represents an exciting area of investigation in this disease.Long-term follow-up of patients treated with rituximab with short maintenance (one dose per week 3 4 followed by single dose every 2 months 3 4) demonstrates a 10-year progression-free survival (PFS) estimate of 44%. 5 Recently, a study from LYSA reported a complete metabolic response (CMR) rate of 59% and a 4-year PFS of 58% with subcutaneous rituximab followed by short maintenance in firstline low-tumor burden FL. 6 These studies suggest that a fraction of patients with low-tumor burden FL may be cured with monoclonal antibody therapy.Mosunetuzumab is a CD20xCD3 bispecific antibody, US Food and Drug Administration-approved for treatment of FL after two previous therapies.In previously untreated, low-tumor burden FL, treatment with mosunetuzumab resulted in a CMR rate of 87%.7 Toxicities were limited to low-grade cytokine release syndrome, rash, and infections, without any significant neurotoxicity.In FL, achieving a CMR translates to improved PFS. 8 Because of the high CMR rate of mosunetuzumab in low-tumor burden FL, we hypothesize a significant PFS benefit with mosunetuzumab over rituximab.Moreover, using these therapies as first line in the low-tumor burden setting should result in decreased T-cell exhaustion, thus increasing the probability of a T-cell-engaging therapy to be active.The goal of this study is to evaluate the potential to cure FL with short-and fixedduration monoclonal antibody therapy, directly comparing mosunetuzumab with rituximab in a phase III randomized clinical trial.
Autor:innen und Institutionen
- Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, NC.
- SWOG Statistics & Data Management Center, Fred Hutchinson Cancer Center, Seattle, WA.
- Brown University, Providence, RI.
- Georgia Cancer Center, Augusta University, Augusta, GA.
- City of Hope Comprehensive Cancer Center, Duarte, CA.
- University of Chicago, Chicago, IL.
ORCID-Profile: Nilanjan Ghosh, Hongli Li, Adam J Olszewski, Locke Bryan
Förderung
- NCI NIH HHS
Zitieren
APA
Ghosh, N., Bellasea, S., Li, H., Olszewski, A. J., Bryan, L., Danilov, A., Smith, S., LeBlanc, M., & Friedberg, J. W. (2025). SWOG 2308: Randomized Phase III Study of Mosunetuzumab Versus Rituximab for Low–Tumor Burden Follicular Lymphoma. JCO Oncology Advances. https://doi.org/10.1200/oa-25-00037
Vancouver
Ghosh N, Bellasea S, Li H, Olszewski AJ, Bryan L, Danilov A, et al. SWOG 2308: Randomized Phase III Study of Mosunetuzumab Versus Rituximab for Low–Tumor Burden Follicular Lymphoma. JCO Oncology Advances. 2025. doi:10.1200/oa-25-00037
BibTeX
@article{Ghosh2025,
author = {Ghosh, Nilanjan and Bellasea, Shay and Li, Hongli and Olszewski, Adam J and Bryan, Locke and Danilov, Alexey and Smith, Sonali and LeBlanc, Michael and Friedberg, Jonathan W},
title = {SWOG 2308: Randomized Phase III Study of Mosunetuzumab Versus Rituximab for Low–Tumor Burden Follicular Lymphoma},
journal = {JCO Oncology Advances},
year = {2025},
number = {2},
doi = {10.1200/oa-25-00037}
}
EUVIMED